Skip to main content
Uncategorized

Intelligent Pharma, a success story at the series of CTecno Breakfasts

By 23 de May de 2013November 18th, 2020No Comments
< Back to news
Víctor Bautista, Ignasi Belda and Montserrat Vendrell with debate moderator Xavier Monzó - Photo: © CTecno.
 23.05.2013

Intelligent Pharma, a success story at the series of CTecno Breakfasts

More than 70 people attended yesterday's breakfast-networking that CTecno (Technology Centre of Catalonia) dedicated to biotechnology, biomedicine and ICT, at the Auditori de Barcelona Activa. The event was attended by Biocat CEO, Montserrat Vendrell, who gave the talk 'technologies to address new challenges in biotechnology and health" and entrepreneurs Ignasi Belda, CEO of Intelligent Pharma, and Victor Bautista, CEO of SocialDiabetes, who explained their success stories.


Intelligent Pharma is headquartered at the Barcelona Science Park and has been working for almost a decade ago, in R & D of new computer-based technologies mainly in artificial intelligence and supercomputing-to accelerate and reduce costs in the design process of new drugs. Founded in 2007 by a young entrepreneur, engineer Ignasi Belda, ,the company currently has subsidiaries in three countries in the world (Germany, United Kingdom and United States), plus a strong network of clients in Europe, North America , Latin America and Asia and has received numerous awards for being one of the most innovative companies in the country, such as the XXI Entrepreneur Award (2010) and the BioEmprendedor XXI Prize (2008).

During his talk, Ignasi Belda explained that ICT applied to biopharmaceutical research is a source of innovation and development of new drugs, while also saving time and resources in the production process. The discovery of a new drug is a long process (about 12 years), expensive (about one billion Euros) and quite risky (only one out of 15 projects end up becoming a drug). “We start with a molecule and you don’t know what side effects it will have.” Using computational chemistry we can move this prediction forward”, said the entrepreneur.

The company has developed a large portfolio of computational technologies that allows it to provide a wide range of services to the pharmaceutical industry in the early stages of research of new medicines, from molecular optimization to the computational discovery of mechanisms of action. In this sense, Belda also said that in his experience “pharmaceutical companies have saved up to two years and €20 millions on research.”